Search Within

Lymphoma

Formats
  1. Meeting Abstract (1382)
  2. Journal Article (1054)
  3. Book Section (64)
  4. Review (63)
  5. Editorial (38)
  6. Research Letter (38)
  7. Guidelines (18)
  8. Conference Paper (15)
  9. Correspondence (11)
  10. Miscellaneous (5)
  11. Book Whole (4)
Groups
  1. Center for Hematologic Malignancies (2692)
  2. Department of Medicine (2692)
  3. Hematologic Malignancies, Division of (2692)
  4. Population Sciences Research Program (742)
  5. Survivorship Research (653)
  6. Executive Committee, Center for Hematologic Malignancies (391)

More Groups

People
  1. Andrew Zelenetz (781)
  2. Steven Horwitz (664)
  3. Maria Palomba (442)
  4. Ariela Noy (369)
  5. David Straus (360)
  6. Alison Moskowitz (355)

More People

Years
  1. 2025 (39)
  2. 2024 (141)
  3. 2023 (180)
  4. 2022 (170)
  5. 2021 (171)
  6. 2020 (170)

More Years

Publications
  1. Blood (875)
  2. Journal of Clinical Oncology (275)
  3. Hematological Oncology (110)
  4. British Journal of Haematology (81)
  5. Leukemia and Lymphoma (81)
  6. Haematologica (71)

More Publications

Publishers
  1. American Society of Hematology (940)
  2. American Society of Clinical Oncology (291)
  3. Elsevier Inc. (187)
  4. Wiley Blackwell (174)
  5. John Wiley & Sons (96)
  6. Nature Publishing Group (93)

More Publishers

Results (2692)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Hodgkin's disease
    Book Section

    Yahalom, J.; Straus, D.
    In Pazdur, R.; Coia, L. R.; Hoskins, W. J.; Wagman, L. D. (Eds.) Cancer Management: A Multidisciplinary Approach. 5th ed (2001)

    Fulltext@MSK | Save
  • Dosimetry optimizes tumor dose & enhances safety in non-hodgkins lymphoma patients [PTS] treated with I-131 tositumomab [Bexxar ™]
    Meeting Abstract

    Goldsmith, S. J.; Kaminski, M.; Wahl, R.; Vose, J.; Zelenetz, A.; Kroll, S.; Clapp, K.; Leonard, J. L.; Presbyterian, N. Y.
    Journal of Nuclear Medicine (2001)

    Fulltext@MSK | Save
  • Results of a randomized study of Bexxar (TM) (tositumomab and iodine I 131 tositumomab) vs. unlabeled tositumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma (NHL)
    Meeting Abstract

    Davis, T. A.; Kaminski, M. S.; Leonard, J. P.; Gregory, S. A.; Wahl, R.; Hsu, F. J.; Wilkinson, M.; Frankel, S. R.; Serafini, A.; Zelenetz, A. D.; more...
    Blood (2001)

    Fulltext@MSK | Save
  • Results of a prospective randomized trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) alone vs. ABVD plus radiation therapy for early stage non bulky Hodgkin's disease
    Meeting Abstract

    Straus, D. J.; Yahalom, J.; Zelenetz, A. D.; Qin, J.; Myers, J.; Moskowitz, C. H.; Noy, A.; Bertino, J. R.; Portlock, C. S.
    Blood (2001)

    Fulltext@MSK | Save
  • Gene amplification in diffuse large B-cell lymphoma (DLBCL) detected by array-based screening predicts clinical outcome
    Meeting Abstract

    Chen, W. Y.; Chaganti, S.; Donnelly, G. B.; Qin, J.; Lane, D.; Ruffalo, T.; Teruya-Feldstein, J.; Zelenetz, A. D.; Houldsworth, J.; Chaganti, R. S. K.
    Blood (2001)

    Fulltext@MSK | Save
  • Phase II study of accelerated fractionation involved field radiotherapy (IFRT), total body irradiation (TBI), ifosfamide and continuous infusion etoposide with autologous stem cell transplantation (ASCT) in the treatment of patients with relapsed and primary refractory aggressive non-Hodgkins lymphoma (NHL)
    Meeting Abstract

    Moskowitz, C. H.; Yahalom, J.; Zelenetz, A. D.; Kewalramani, T.; Malhotra, S.; Nimer, S. D.
    Blood (2001)

    Fulltext@MSK | Save
  • PDX, a novel antifolate with potent in vitro and in vivo activity in non-Hodgkin's lymphoma
    Meeting Abstract

    Wang, E. S.; O'connor, O.; Zhang, K.; She, Y.; Zelenetz, A.; Sirotnak, F. M.; Moore, M. A. S.
    Blood (2001)

    Fulltext@MSK | Save
  • Clinical development of the histone deacetylase inhibitor suberoylanalide hydroxamic acid (SAHA) in aggressive non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD)
    Meeting Abstract

    O'Connor, O. A.; Kelly, W.; Wang, E. S.; Richon, V.; Moskowitz, C.; Tong, W.; Donnelly, G.; Zelenetz, A. D.; Moore, M. A. S.; Rifkind, R. A.; more...
    Blood (2001)

    Fulltext@MSK | Save
  • Bexxar (TM) (tositumomab and iodine I 131 tositumomab) results in durable long-term responses in patients with poor prognosis, multiple relapsed (rel), and refractory (ref) low-grade or transformed low-grade non-Hodgkins lymphoma (NHL)
    Meeting Abstract

    Leonard, J. P.; Zelenetz, A. D.; Vose, J. M.; Coleman, M.; Clapp, K. J.; Kaminski, M. S.
    Blood (2001)

    Fulltext@MSK | Save
  • Molecular cytogenetc analysis of genomic instability at the 1q12 -> q22 chromosomal site in B-cell non-Hodgkin's lymphoma
    Meeting Abstract

    Itoyama, T.; Nanjangud, G.; Chen, W. Y.; Dyomin, V. G.; Teruya-Feldstein, J.; Jhanwar, S. C.; Zelenetz, A. D.; Chaganti, R. S. K.
    Blood (2001)

    Fulltext@MSK | Save